Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724301 | 0.84 | GAA (0.58) | GAAPKMMEN1KMT2AATM | |
| SCHEMBL6581959 | 0.79 | SMN1; SMN2 (0.79) | GAAPKMMEN1KMT2AATM | |
| SCHEMBL10064240 | 0.77 | GAA (0.64) | GAAPKMMEN1KMT2ATSHR | |
| SCHEMBL15531462 | 0.75 | ALDH1A1 (0.75) | GAAPKMKMT2ATSHRALDH1A1 | |
| SCHEMBL732936 | 0.75 | GAA (0.76) | GAAPKMMEN1KMT2ATSHR | |
| SCHEMBL10064232 | 0.74 | PKM (0.74) | GAAPKMMEN1KMT2AATM | |
| SCHEMBL4264994 | 0.74 | CNR1 (1.00) | GAAPKMKMT2ATSHRALDH1A1 | |
| SCHEMBL10722408 | 0.74 | HSD11B1 (0.77) | GAAMEN1KMT2AATMTSHR | |
| SCHEMBL3967794 | 0.74 | HSD11B1 (0.77) | GAAMEN1KMT2AATMTSHR | |
| SCHEMBL24322677 | 0.73 | PKM (0.65) | PKMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | claimed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | claimed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | claimed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-2004619-A1 | 1-PHENYLSULFONYL-DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AS MODULATORS OF HYDROXSTEROID DEHYDROGENASES | Amgen Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007111921-A1 | 1-PHENYLSULFONYL-DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AS MODULATORS OF HYDROXSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | GPR119, GLP1R, INSR | GAA 517/4885PKM 1084/4885MEN1 989/4885 |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | GPR119, GLP1R, INSR | GAA 517/4885PKM 1084/4885MEN1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.